304 related articles for article (PubMed ID: 25143484)
1. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.
Hoellein A; Fallahi M; Schoeffmann S; Steidle S; Schaub FX; Rudelius M; Laitinen I; Nilsson L; Goga A; Peschel C; Nilsson JA; Cleveland JL; Keller U
Blood; 2014 Sep; 124(13):2081-90. PubMed ID: 25143484
[TBL] [Abstract][Full Text] [Related]
2. Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis.
Old JB; Kratzat S; Hoellein A; Graf S; Nilsson JA; Nilsson L; Nakayama KI; Peschel C; Cleveland JL; Keller UB
Mol Cancer Res; 2010 Mar; 8(3):353-62. PubMed ID: 20197382
[TBL] [Abstract][Full Text] [Related]
3. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.
Kessler JD; Kahle KT; Sun T; Meerbrey KL; Schlabach MR; Schmitt EM; Skinner SO; Xu Q; Li MZ; Hartman ZC; Rao M; Yu P; Dominguez-Vidana R; Liang AC; Solimini NL; Bernardi RJ; Yu B; Hsu T; Golding I; Luo J; Osborne CK; Creighton CJ; Hilsenbeck SG; Schiff R; Shaw CA; Elledge SJ; Westbrook TF
Science; 2012 Jan; 335(6066):348-53. PubMed ID: 22157079
[TBL] [Abstract][Full Text] [Related]
4. Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma.
Li S; He X; Gan Y; Zhang J; Gao F; Lin L; Qiu X; Yu T; Zhang X; Chen P; Tong J; Qian W; Xu Y
Theranostics; 2021; 11(7):3439-3451. PubMed ID: 33537096
[No Abstract] [Full Text] [Related]
5. EBV latent membrane protein 2A orchestrates p27
Fish K; Sora RP; Schaller SJ; Longnecker R; Ikeda M
Blood; 2017 Dec; 130(23):2516-2526. PubMed ID: 29074502
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma.
Fish K; Chen J; Longnecker R
Blood; 2014 Jan; 123(4):530-40. PubMed ID: 24174629
[TBL] [Abstract][Full Text] [Related]
7. IBTK contributes to B-cell lymphomagenesis in Eμ-myc transgenic mice conferring resistance to apoptosis.
Vecchio E; Golino G; Pisano A; Albano F; Falcone C; Ceglia S; Iaccino E; Mimmi S; Fiume G; Giurato G; Britti D; Scala G; Quinto I
Cell Death Dis; 2019 Apr; 10(4):320. PubMed ID: 30975981
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced tumorigenesis.
Sluss HK; Gannon H; Coles AH; Shen Q; Eischen CM; Jones SN
Mol Cancer Res; 2010 Feb; 8(2):216-22. PubMed ID: 20145032
[TBL] [Abstract][Full Text] [Related]
9. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.
den Hollander J; Rimpi S; Doherty JR; Rudelius M; Buck A; Hoellein A; Kremer M; Graf N; Scheerer M; Hall MA; Goga A; von Bubnoff N; Duyster J; Peschel C; Cleveland JL; Nilsson JA; Keller U
Blood; 2010 Sep; 116(9):1498-505. PubMed ID: 20519624
[TBL] [Abstract][Full Text] [Related]
10. Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis.
Keller UB; Old JB; Dorsey FC; Nilsson JA; Nilsson L; MacLean KH; Chung L; Yang C; Spruck C; Boyd K; Reed SI; Cleveland JL
EMBO J; 2007 May; 26(10):2562-74. PubMed ID: 17464290
[TBL] [Abstract][Full Text] [Related]
11. Mouse genetics suggests cell-context dependency for Myc-regulated metabolic enzymes during tumorigenesis.
Nilsson LM; Forshell TZ; Rimpi S; Kreutzer C; Pretsch W; Bornkamm GW; Nilsson JA
PLoS Genet; 2012; 8(3):e1002573. PubMed ID: 22438825
[TBL] [Abstract][Full Text] [Related]
12. Skp2 is necessary for Myc-induced keratinocyte proliferation but dispensable for Myc oncogenic activity in the oral epithelium.
Sistrunk C; Macias E; Nakayama K; Kim Y; Rodriguez-Puebla ML
Am J Pathol; 2011 Jun; 178(6):2470-7. PubMed ID: 21641375
[TBL] [Abstract][Full Text] [Related]
13. SAE1 promotes human glioma progression through activating AKT SUMOylation-mediated signaling pathways.
Yang Y; Liang Z; Xia Z; Wang X; Ma Y; Sheng Z; Gu Q; Shen G; Zhou L; Zhu H; Xu N; Liang S
Cell Commun Signal; 2019 Jul; 17(1):82. PubMed ID: 31345225
[TBL] [Abstract][Full Text] [Related]
14. The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma.
Newbold A; Salmon JM; Martin BP; Stanley K; Johnstone RW
Oncogene; 2014 Nov; 33(47):5415-23. PubMed ID: 24292681
[TBL] [Abstract][Full Text] [Related]
15. PIAS1 Promotes Lymphomagenesis through MYC Upregulation.
Rabellino A; Melegari M; Tompkins VS; Chen W; Van Ness BG; Teruya-Feldstein J; Conacci-Sorrell M; Janz S; Scaglioni PP
Cell Rep; 2016 Jun; 15(10):2266-2278. PubMed ID: 27239040
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary B cells into malignant cells.
Nakagawa M; Tsuzuki S; Honma K; Taguchi O; Seto M
Haematologica; 2011 Sep; 96(9):1318-26. PubMed ID: 21606168
[TBL] [Abstract][Full Text] [Related]
17. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice.
Kelly PN; Grabow S; Delbridge AR; Strasser A; Adams JM
Blood; 2011 Dec; 118(24):6380-6. PubMed ID: 21998213
[TBL] [Abstract][Full Text] [Related]
18. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
19. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
[TBL] [Abstract][Full Text] [Related]
20. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
